Citius Pharmaceuticals Projected to Reach Profitability by 2027

Financial analysts project that Citius Pharmaceuticals (CTXR) will transition from a loss-making entity to a profitable one by 2027. The company is estimated to achieve positive net income of approximately $78 million during that fiscal year, supported by a robust projected annual growth rate of nearly 48%. In addition to strong growth prospects, the company maintains a healthy balance sheet with a debt-to-equity ratio of just 1.3%. This low leverage indicates disciplined financial management and provides a solid foundation for future operations without heavy reliance on debt. While the path to breakeven spans several years, the long-term outlook for the NASDAQ-listed stock remains optimistic. Investors are closely monitoring the company's ability to execute its growth strategy efficiently.